b'In adult patients with CKD associated with T2D 83 With KERENDIA ( nerenone),a different pathway leads to different possibilities 1,2KERENDIA offers a different path forward KERENDIA is therst and only selective MRA with a nonsteroidal structure KERENDIA blocks MR overactivation, which is thought to contribute to in ammation andbrosis that can lead to CKD progression In adults with CKD associated with T2D, KERENDIA is proven to slow CKD progression and reduce risk of CV eventsLearn more about KERENDIA and the FIDELIO-DKD trialINDICATION: DRUG INTERACTIONS:KERENDIA is indicated to reduce the risk of sustained eGFRStrong CYP3A4 Inhibitors: Concomitant use of KERENDIA decline, end-stage kidney disease, cardiovascular death,with strong CYP3A4 inhibitors is contraindicated. Avoid non-fatal myocardial infarction, and hospitalization for heartconcomitant intake of grapefruit or grapefruit juicefailure in adult patients with chronic kidney disease (CKD)Moderate and Weak CYP3A4 Inhibitors: Monitor serum associated with type 2 diabetes (T2D) potassium during drug initiation or dosage adjustment of IMPORTANT SAFETY INFORMATION either KERENDIA or the moderate or weak CYP3A4 inhibitor CONTRAINDICATIONS:and adjust KERENDIA dosage as appropriateConcomitant use with strong CYP3A4 inhibitors Strong and Moderate CYP3A4 Inducers: AvoidPatients with adrenal insuf ciency concomitant use of KERENDIA with strong or moderate WARNINGS AND PRECAUTIONS: CYP3A4 inducersHyperkalemia: KERENDIA can cause hyperkalemia. The riskUSE IN SPECIFIC POPULATIONS:for developing hyperkalemia increases with decreasing kidneyLactation: Avoid breastfeeding during treatment with function and is greater in patients with higher baselineKERENDIA and for 1 day after treatment potassium levels or other risk factors for hyperkalemia. MeasureHepatic Impairment: Avoid use of KERENDIA in patients with serum potassium and eGFR in all patients before initiation ofsevere hepatic impairment (Child Pugh C) and consider treatment with KERENDIA and dose accordingly. Do not initiateadditional serum potassium monitoring with moderate hepatic KERENDIA if serum potassium is 5.0 mEq/L impairment (Child Pugh B) Measure serum potassium periodically during treatment withPlease read the Brief Summary of the KERENDIA KERENDIA and adjust dose accordingly. More frequentPrescribing Information on the following pages.monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications thatCKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerularltration rate; MR=mineralocorticoid receptor; MRA=mineralocorticoid receptor antagonist; T2D=type impair potassium excretion or increase serum potassium 2 diabetes. References: 1. KERENDIA [prescribing information]. Whippany, NJ: Bayer HealthCareMOST COMMON ADVERSE REACTIONS: Pharmaceuticals, Inc; July 2021. 2. Bakris GL et al. N Engl J Med. 2020;383(23):2219-2229. Adverse reactions reported in 1% of patients on KERENDIAand more frequently than placebo: hyperkalemia (18.3% vs. 9%), hypotension (4.8% vs. 3.4%), and hyponatremia (1.4% vs. 0.7%) 2022 Bayer. BAYER, the Bayer Cross, and KERENDIA are registered trademarks of Bayer.All rights reserved. MAC-KER-US-0079-1 04/22'